INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (17,041)	$ (19,382)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	1,590	$ 1,498
Loss from sale of property and equipment, net	(3)
Accretion of discount, amortization of premium and changes in accrued interest of marketable securities	41	$ 233
Gain from sale of investments of available-for-sale marketable securities	303	290
Stock-based compensation to employees, directors and non-employees consultants	2,367	2,912
Decrease in Office of the Chief Scientist receivables	1,511	2,059
Decrease (increase) in other accounts receivable	1,038	(641)
Decrease in trade payables	(888)	(836)
Increase (decrease) in other accounts payable, accrued expenses and other long-term liabilities	1,054	(1,267)
Decrease in deferred revenues	(2,847)	(285)
Decrease in advance payment from United Therapeutics	(93)	(123)
Increase in interest receivable on short-term deposits	(33)	19
Linkage differences and interest on short and long-term deposits	(13)	(5)
Accrued severance pay, net	36	(60)
Net cash used by operating activities	(12,978)	(15,588)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(1,535)	(638)
Repayment of (investment in) short-term deposits	(3,524)	12,511
Repayment of long-term deposits	4	$ 10
Proceeds from sale of property and equipment	29
Proceeds from sale of available-for-sale marketable securities	2,863	$ 9,879
Proceeds from redemption of available-for-sale marketable securities	1,066	440
Investment in available-for-sale marketable securities	(3,954)	(3,528)
Net cash provided by (used in) investing activities	(5,051)	18,674
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds related to issuance of common stock in a private placement	790	1,114
Exercise of options and warrants	17	251
Net cash provided by financing activities	807	1,365
Increase (decrease) in cash and cash equivalents	(17,222)	4,451
Cash and cash equivalents at the beginning of the period	22,626	4,493
Cash and cash equivalents at the end of the period	5,404	8,944
(a) Supplemental disclosure of cash flow activities:
Taxes paid due to non-deductible expenses	50	47
(b) Supplemental disclosure of non-cash activities:
Purchase of property and equipment on credit	200	$ 9
Share consideration to contractor	$ 39